Results 101 to 110 of about 21,988 (154)

Time to Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis and Its Predictors: A National, Multicenter, Retrospective Cohort [PDF]

, 2012
Ruben Tavares, Janet Pope, JEAN-LUC TREMBLAY, CARTER THORNE, VIVIAN P. BYKERK, JURIS LAZOVSKIS, KENNETH L.N. BLOCKA, MARY J. BELL, Diane Lacaille, Carol Hitchon, AVRIL A. FITZGERALD, WESLEY K. FIDLER, ARTHUR A.M. BOOKMAN, JAMES M. HENDERSON, DIANNE P. MOSHER, DALTON E. SHOLTER, Majed Khraishi, Boulos Haraoui, HONG CHEN, XIUYING LI, Andreas Laupacis, Gilles Boire, George Tomlinson, Claire Bombardier   +23 more
openalex   +1 more source

Preferences for Tapering Biologic Disease-Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. [PDF]

Arthritis Care Res (Hoboken)
Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, Marra CA.   +7 more
europepmc   +1 more source

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis. [PDF]

Intern Med, 2023
Hasegawa E, Ito S, Kurosawa Y, Kobayashi D, Otani H, Abe A, Nakazono K, Murasawa A, Narita I, Ishikawa H.   +9 more
europepmc   +1 more source

Complications of invasive oral procedures in patients with immune-mediated inflammatory disorders treated with biological and conventional disease-modifying antirheumatic drugs or glucocorticoids: a scoping review of the literature. [PDF]

BMC Oral Health
Radoi L, Kadri M, Gosset M.
europepmc   +1 more source

Editorial: Disease-modifying antirheumatic drugs: Approaches and lessons learned from traditional medicine. [PDF]

Front Pharmacol, 2023
Mei L, Gao K, He X, Jakobsson PJ, Huang R.   +4 more
europepmc   +1 more source

Facilitators and Barriers to Adherence in the Initiation Phase of Disease-modifying Antirheumatic Drug (DMARD) Use in Patients with Arthritis Who Recently Started Their First DMARD Treatment [PDF]

, 2014
Annelieke Pasma, Adriaan van ’t Spijker, Jolanda J. Luime, Margot Walter, Jan J.V. Busschbach, Johanna M W Hazes   +5 more
openalex   +1 more source

Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. [PDF]

RMD Open, 2023
Rudwaleit M, Mørup MF, Humphries B, Zannat NE, Willems D, Taieb V, Boonen A.   +6 more
europepmc   +1 more source

Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical Remission. Do Biologics Perform Better Than Synthetic Antirheumatic Drugs? [PDF]

, 2014
Elena Ciubotariu, Cem Gabay, Axel Finckh
openalex   +1 more source

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database. [PDF]

Front Pharmacol
Xiong W, Li Y, Hu L, He G, Huang J.
europepmc   +1 more source

Use of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Supporting Shared Decision-Making Between Patients With Cancer and Clinicians. [PDF]

ACR Open Rheumatol, 2023
Singh N, Grivas P, Makris UE, Suarez-Almazor ME, O'Hare AM, Barton JL.   +5 more
europepmc   +1 more source